Zhitong Finance App learned that according to the Hong Kong Stock Exchange's disclosure on July 16, Immvira Bioscience Inc. (abbreviation: Inuowei Pharmaceuticals) submitted a listing application to the main board of the Hong Kong Stock Exchange, with Citibank and CICC as co-sponsors. According to the prospectus, Inuowei Pharmaceutical is a biotechnology company focusing on clinical needs. It is committed to the discovery, development, production and commercialization of novel oncolytic immunotherapy and engineered exosome therapies. The company has established a product pipeline, including two tumolytic immunotherapy products for solid tumors and five engineered exosome products with clinical application prospects or direct commercialization.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.